Pharmaceutical composition for treating fibrosis

A pharmaceutical composition and compound technology, applied in the direction of drug combination, active ingredients of heterocyclic compounds, drug delivery, etc., can solve problems such as ambiguity, high frequency, and serious side effects

Pending Publication Date: 2021-04-16
LTT BIO PHARMA +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These medicines have suppressed the decline in forced vital capacity (FVC) of IPF patients in clinical trials (non-patent literature 1 to 3), but their effectiveness in long-term use is unclear.
In addition, both drugs cause frequent and serious side effects, especially gastrointestinal disturbances, which have become a problem (Non-Patent Documents 2 and 3)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating fibrosis
  • Pharmaceutical composition for treating fibrosis
  • Pharmaceutical composition for treating fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0125] a.Experimental method

[0126] (1) Administration of bleomycin (BLM), idebenone, tolperisone and eperisone

[0127] For male ICR mice under normal feeding, BLM was administered through the respiratory tract on the first day to make BLM lung injury model mice.

[0128] Pre-administration: From the first day to the seventh day, idebenone was administered through the respiratory tract once a day. On the first day, idebenone was administered through the respiratory tract 1 hour before BLM administration.

[0129] Subsequent administration: From the 10th day to the 18th day, idebenone was administered through the respiratory tract once a day. Both drugs were suspended in 0.9% NaCl before use.

[0130] Post-administration: From the 10th day to the 19th day, tolperone was administered once a day. Both drugs were suspended in 0.9% NaCl before use.

[0131] Post-administration: Eperisone was administered once a day from the 10th day to the 19th day. Both drugs were suspend...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

To provide a novel therapeutic agent for fibrosis that induces selective cell death of lung fibroblasts without injuring alveolar epithelial cells and thus inhibits lung fibrosis. A pharmaceutical composition for treating fibrosis that comprises a compound represented by formula (I) or (II), a pharmaceutically acceptable salt thereof, or a solvate of the same. [In formula (I): R1 represents an optionally halogenated C1-4 alkyl group; and l represents an integer of 3-6. In formula (II): n represents an integer of 8-12.].

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating fibrosis. Background technique [0002] Idiopathic pulmonary fibrosis (idiopathic pulmonary fibrosis; IPF) is a chronic disease with poor prognosis, and the median survival period after diagnosis is very short, ranging from 2.8 to 4.2 years. So far, steroids and immunosuppressants have been used as therapeutic drugs for IPF, but large-scale clinical trials have reported no effect. In addition, two new drugs, pirfenidone and nintedanib, have been marketed in recent years as anti-fibrotic drugs. These medicines have suppressed the decline in forced vital capacity (FVC) of IPF patients in clinical trials (Non-Patent Documents 1 to 3), but their effectiveness in long-term use is unclear. In addition, both drugs cause frequent and severe side effects, especially gastrointestinal disturbances, which have become a problem (Non-Patent Documents 2 and 3). Therefore, it is very important to de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4453A61K31/122A61K31/397A61K31/40A61K31/55A61P1/16A61P9/00A61P11/00A61P13/12A61P17/00C07C50/28C07D211/14
CPCA61P17/00A61P9/00A61K31/4453A61K31/40A61P11/00A61P13/12A61K31/55A61P1/16A61K31/397A61K31/122C07D211/14C07C50/28C07C2601/16A61K31/396A61K9/0053A61K9/007
Inventor 水岛彻田中健一郎
Owner LTT BIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap